Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors.

Newman, R A

Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. [electronic resource] - Anti-cancer drugs Nov 1999 - 889-94 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

0959-4973

10.1097/00001813-199911000-00004 doi


Adult
Aged
Agranulocytosis--chemically induced
Antineoplastic Agents--adverse effects
Area Under Curve
Female
Humans
Indoles--adverse effects
Infusions, Intravenous
Male
Maximum Tolerated Dose
Middle Aged
Nausea--chemically induced
Neoplasms--drug therapy
Pyridines--adverse effects
Treatment Outcome